Ítem
Solo Metadatos

Evaluating the immunogenicity of chemically-synthesised peptides derived from foot-and-mouth disease VP1, VP2 and VP3 proteins as vaccine candidates

Mostrar el registro sencillo de la publicación
dc.creatorAvendaño, Catalinaspa
dc.creatorCelis-Giraldo, Carmenspa
dc.creatorOrdoñez, Diegospa
dc.creatorDíaz Arévalo, Diana
dc.creatorRodríguez-Habibe, Ibettspa
dc.creatorOviedo, Jairospa
dc.creatorCurtidor, Hernandospa
dc.creatorGarcía-Castiblanco, Sebastiánspa
dc.creatorMartínez-Panqueva, Fredyspa
dc.creatorCamargo-Castañeda, Andreaspa
dc.creatorReyes, Césarspa
dc.creatorBohórquez, Michel D.spa
dc.creatorVanegas, Magnoliaspa
dc.creatorCantor, Danielaspa
dc.creatorPatarroyo, Manuel E.spa
dc.creatorPatarroyo, Manuel A.spa
dc.date.accessioned2020-05-26T00:02:15Z
dc.date.available2020-05-26T00:02:15Z
dc.date.created2020spa
dc.description.abstractFoot-and-mouth disease (FMD) is one of the most contagious veterinary viral diseases known, having economic, social and potentially devastating environmental impacts. The vaccines currently being marketed/sold around the world for disease control and prevention in bovines do not stimulate the production of antibodies having crossed reactions to different serotypes. This means that if an animal becomes infected by a serotype which has not been included in a vaccine then it will develop the disease. Synthetic peptide vaccines represent a safer option and (depending on the design) can stimulate antibodies protecting against different variants. Based on the forgoing, this work was aimed at evaluating FMDV VP1, VP2 and VP3 protein-derived, modified and chemically-synthesised peptides’ ability to induce an immune response for developing a vaccine contributing towards controlling the disease. VP1, VP2 and VP3 proteins’ conserved regions were selected for this. Peptides from these regions were chemically synthesised; binding assays were then carried out for ascertaining whether they were involved in BHK-21 cell binding. Selected peptides’ structure and location were studied. Peptides which did bind were modified and formulated with Montanide ISA 70 adjuvant; 17 animals were immunised twice with the formulation. The animals were genotyped by amplifying the BoLA-DRB3.2 gene. Blood samples were taken from 17 cattle on day 43 post-first immunisation for studying the formulation's immunogenicity. The sera were used in ELISA, immunofluorescence, flow cytometry, immunoadsorption and seroneutralisation assays. The A24 Cruzeiro and O1 Campos virus serotypes were used for these assays. The results revealed that even though protein exposure and 3D structure might be different amongst serotypes, the antibodies so produced could inhibit virus entry to cells, thereby showing the selected peptides’ in vitro protection-inducing ability. © 2020 Elsevier Ltdeng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.vaccine.2020.04.006
dc.identifier.issn0264410X
dc.identifier.issn13588745
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23463
dc.language.isoengspa
dc.publisherElsevier Ltdspa
dc.relation.citationEndPage3951
dc.relation.citationIssueNo. 23
dc.relation.citationStartPage3942
dc.relation.citationTitleVaccine
dc.relation.citationVolumeVol. 38
dc.relation.ispartofVaccine, ISSN:0264410X, 13588745, Vol.38, No.23 (2020); pp. 3942-3951spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85083301641&doi=10.1016%2fj.vaccine.2020.04.006&partnerID=40&md5=ff04037bef0e0b0373920c220f0a78daspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordA24 Cruzeiro serotypespa
dc.subject.keywordCapsid proteinsspa
dc.subject.keywordFoot-and-mouth disease virusspa
dc.subject.keywordO1 Campos serotypespa
dc.subject.keywordSynthetic peptidespa
dc.titleEvaluating the immunogenicity of chemically-synthesised peptides derived from foot-and-mouth disease VP1, VP2 and VP3 proteins as vaccine candidatesspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos